Phase I study of trifluridine/tipiracil (TAS-102) plus irinotecan in combination with bevacizumab as a second-line therapy for patients with metastatic colorectal cancer.
Jing ZhangWenwei YangJunbao LiuNan WangZhaoying RenTingting YangGongli XieGuifu WuYongkun SunPublished in: Investigational new drugs (2024)
The regimen of TAS-102, irinotecan, and bevacizumab is tolerable with antitumor activity for metastatic colorectal cancer patients refractory to first-line fluoropyrimidines and oxaliplatin treatment.